Butt Muhammad Daoud, Ong Siew Chin, Rafiq Azra, Batool Nighat, Saifi Rumana, Yaseen Samina, Kaukab Irum, Ramzan Basit
School of Pharmaceutical Sciences, Universiti Sains Malaysia, USM Penang, Malaysia.
Department of Medicine, Faculty of Medicine, Centre of Excellence for Research in AIDS, University of Malaya, Kuala Lumpur, Malaysia.
J Pharm Policy Pract. 2024 Dec 4;17(1):2432462. doi: 10.1080/20523211.2024.2432462. eCollection 2024.
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated efficacy in improving glycemic control and promoting weight loss in clinical trials. However, real-world data from diverse populations, particularly from South Asia, are limited. The study aims to evaluate the long-term efficacy and safety of liraglutide in a real-world setting among Pakistani patients with type 2 diabetes mellitus (T2DM).
A retrospective cohort study of 624 patients initiated on liraglutide was conducted. Data were collected at baseline and 6, 12, 18, and 24 months. Primary outcomes were HbA1c and weight changes. Secondary outcomes included fasting plasma glucose, lipid profile, and blood pressure. Statistical analyses were performed using appropriate methods.
In study population the mean HbA1c reduction of -1.45 ± 0.67% was observed at 24 months, with 30.6% achieving HbA1c ≤ 7.5%. A rapid and sustained weight loss of -7.51 kg was achieved, with 27.2% experiencing ≥5% weight loss. Additionally, liraglutide led to a significant reduction in LDL cholesterol, with 46.7% of patients achieving a ≥ 10% reduction at 24 months. Liraglutide was well-tolerated, with a low discontinuation rate of 4.6%.
Liraglutide demonstrated sustained efficacy and safety in a diverse Pakistani population with T2DM, regardless of baseline characteristics. These findings support the use of liraglutide as an effective treatment option for T2DM in real-world clinical practice.
利拉鲁肽是一种胰高血糖素样肽-1（GLP-1）受体激动剂，在临床试验中已证明其在改善血糖控制和促进体重减轻方面具有疗效。然而，来自不同人群，尤其是南亚人群的真实世界数据有限。本研究旨在评估利拉鲁肽在巴基斯坦2型糖尿病（T2DM）患者的真实世界环境中的长期疗效和安全性。
对624例开始使用利拉鲁肽的患者进行了一项回顾性队列研究。在基线以及6、12、18和24个月时收集数据。主要结局为糖化血红蛋白（HbA1c）和体重变化。次要结局包括空腹血糖、血脂谱和血压。使用适当的方法进行统计分析。
在研究人群中，24个月时观察到糖化血红蛋白平均降低-1.45±0.67%，30.6%的患者糖化血红蛋白≤7.5%。实现了-7.51 kg的快速且持续的体重减轻，27.2%的患者体重减轻≥5%。此外，利拉鲁肽导致低密度脂蛋白胆固醇显著降低，24个月时46.7%的患者降低≥10%。利拉鲁肽耐受性良好，停药率低至4.6%。
无论基线特征如何，利拉鲁肽在患有T2DM的不同巴基斯坦人群中均显示出持续的疗效和安全性。这些发现支持在真实世界的临床实践中使用利拉鲁肽作为T2DM的有效治疗选择。
